Home › Companies › Tarsus Pharmaceuticals, Inc. › 2024-2025

Tarsus Pharmaceuticals, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and Tarsus Pharmaceuticals, Inc.’s Form 8-K, filed 2025-06-18 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Reported items
216Asset managers
1,452Fund votes
2025-06-12Meeting date

Proxy season: 2024-2025 2025-2026

Explore Tarsus Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Tarsus Pharmaceuticals, Inc.

These tallies are Tarsus Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Tarsus Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2025-06-12
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Bobak Azamian, M.D., Ph.D.	20,770,139	--	--	6,796,180	7,285,501	Majority: yes
Elect Director: Katherine Goodrich, M.D., MHS	26,837,786	--	--	728,533	7,285,501	Majority: yes
The following directors, in addition to Dr. Azamian and Dr.	27,132,839	416,845	16,635	--	7,285,501	Majority: yes
Proposal 3: Advisory Vote on Frequency of Advisory Vote on Named Executive Officer Compensation Our stockholders approved, on an advisory, non-binding basis, conducting, on an every 1 year frequency, future stockholder votes on the compensation of our named ex	26,916,300	--	9,404	--	7,285,501	Outcome not stated
Proposal 4: Ratification of Ernst & Young LLP as our independent registered public accounting firm Our stockholders approved the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year endin	34,718,262	125,755	7,803	--	--	Majority: yes

Source: Tarsus Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2025-06-18 — read the filing on EDGAR.

How asset managers voted at the Tarsus Pharmaceuticals, Inc. 2024-2025 meeting

Each item below shows how the 216 asset managers that disclosed a Tarsus Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Tarsus Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To hold an advisory vote to approve, on a non-binding basis, the frequency with which future stockholder votes on the compensation of our named executive officers will be conducted of one, two or three years.

SECTION 14A SAY-ON-PAY VOTESOutcome not stated

Combines 5 wordings of this item as funds reported it.

— Outcome not stated · no against or withheld count reported

Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Advisory Vote on Frequency of Advisory Vote on Named Executive Officer Compensation Our stockholders approved, on an advisory, non-binding basis, conducting, on an every 1 year frequency, future stockholder v”): 26,916,300 for; no against or withheld count reported, per its Form 8-K filed 2025-06-18 (Item 5.07).

The 210 asset managers below cast 99.8% of the shares they voted on this item FOR (220,045 for, 242 against).

ONE YEAR 72%1 YEAR 24%

FOR: 220,045 (0.7%)AGAINST: 242 (0.0%)ABSTAIN: 760 (0.0%)ONE YEAR: 22,289,371 (72.0%)1 YEAR: 7,406,311 (23.9%)1-YEAR: 520,000 (1.7%)3 YEARS: 492,267 (1.6%)THREE YEARS: 47,692 (0.2%)

Largest asset managers voting on “To hold an advisory vote to approve, on a non-binding basis, the frequency with which future stockholder votes” at Tarsus Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
RTW INVESTMENTS, LP	0	0	0	0	One Year
Vanguard	0	0	0	0	One Year
Paradigm Biocapital Advisors LP	0	0	0	0	One Year
BlackRock	0	0	0	0	1 Year
Frazier Life Sciences Management, L.P.	0	0	0	0	One Year
JENNISON ASSOCIATES LLC	0	0	0	0	1 Year
Invesco	0	0	0	0	One Year
LORD, ABBETT & CO. LLC	0	0	0	0	One Year
Artisan	0	0	0	0	One Year
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	0	0	0	0	One Year
Deep Track Capital, LP	0	0	0	0	1 Year
T. Rowe Price	0	0	0	0	One Year
Citadel	0	0	0	0	One Year
Lord Abbett	0	0	0	0	One Year
Prudential/PGIM	0	0	0	0	One Year
ORBIMED ADVISORS LLC	0	0	0	0	1 Year
GEODE CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
Fidelity	0	0	0	0	One Year
Charles Schwab	0	0	0	0	1 Year
ADAGE CAPITAL PARTNERS GP, L.L.C.	0	0	0	0	1-Year
Waddell & Reed	0	0	0	0	One Year
Ensign Peak Advisors, Inc	0	0	0	0	3 Years
DRIEHAUS CAPITAL MANAGEMENT LLC	0	0	0	0	One Year
State Street	0	0	0	0	One Year
Sands Capital Alternatives, LLC	0	0	0	0	1 Year

Showing the 25 largest of 210 asset managers. See all 210 in the interactive database.

2. To hold an advisory vote to approve, on a non-binding basis, named executive officer compensation.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

98% fund support · no official result

FOR 98%

The 209 asset managers below cast 98% of the shares they voted on this item FOR (28,363,231 for, 498,321 against).

FOR: 28,363,231 (98.3%)AGAINST: 498,321 (1.7%)ABSTAIN: 760 (0.0%)

Largest asset managers voting on “To hold an advisory vote to approve, on a non-binding basis, named executive officer compensation.” at Tarsus Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
RTW INVESTMENTS, LP	3,210,089	0	For
Vanguard	2,252,879	0	For
Paradigm Biocapital Advisors LP	2,053,904	0	For
BlackRock	1,712,448	9,327	For
JENNISON ASSOCIATES LLC	1,261,878	7,168	For
Invesco	936,955	220,068	For
LORD, ABBETT & CO. LLC	999,520	0	For
Artisan	975,107	0	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	874,569	0	For
Deep Track Capital, LP	791,029	0	For
T. Rowe Price	782,292	0	For
Citadel	733,908	0	For
Lord Abbett	669,030	0	For
Prudential/PGIM	663,047	0	For
ORBIMED ADVISORS LLC	653,743	0	For
GEODE CAPITAL MANAGEMENT, LLC	638,640	0	For
Fidelity	587,928	0	For
Charles Schwab	585,372	0	For
Waddell & Reed	499,148	0	For
Ensign Peak Advisors, Inc	487,310	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	450,434	0	For
State Street	438,904	227	For
Rock Springs Capital Management LP	335,244	0	For
Nuveen	288,364	0	For
DE Shaw	278,907	0	For

Showing the 25 largest of 209 asset managers. See all 209 in the interactive database.

3. To elect Class II directors, to serve until the 2028 annual meeting of stockholders or until their respective successor have been elected or appointed: Bobak Azamian

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%WITHHELD 25%

FOR: 20,770,139WITHHELD: 6,796,180

Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Bobak Azamian, M.D., Ph.D.”): 20,770,139 for, 6,796,180 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,995,537 outstanding shares: 49.5% for, 16% withheld (66% of the company cast a for/withheld vote).

The 70 asset managers below cast 100% of the shares they voted on this item FOR (7,298,099 for, 0 against).

FOR 81%ABSTAIN 19%

FOR: 7,298,099 (81.1%)ABSTAIN: 1,700,983 (18.9%)

Largest asset managers voting on “To elect Class II directors, to serve until the 2028 annual meeting of stockholders or until their respective ” at Tarsus Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	2,158,961	0	For
BlackRock	675,182	0	For
Lord Abbett	669,030	0	For
Fidelity	569,050	0	For
Invesco	560,136	0	For
Prudential/PGIM	530,498	12,264	For
Waddell & Reed	0	499,148	Abstain
Artisan	421,491	0	For
T. Rowe Price	328,140	0	For
Charles Schwab	292,606	0	For
TIAA	269,344	0	For
Equitable	165,410	0	For
DRIEHAUS MUTUAL FUNDS	0	161,415	Abstain
Delaware/Macquarie	0	150,000	Abstain
Legg Mason	134,900	0	For
MoA Funds Corp	0	127,541	Abstain
Allspring	0	124,103	Abstain
First Trust	0	107,792	Abstain
Ivy Variable Insurance Portfolios	0	86,002	Abstain
Russell Investments	73,659	0	For
Baird	0	71,895	Abstain
Securian Funds Trust	0	67,303	Abstain
QUANTITATIVE MASTER SERIES LLC	63,024	0	For
SEI	52,645	0	For
Federated Hermes	51,104	0	For

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

4. To elect Class II directors, to serve until the 2028 annual meeting of stockholders or until their respective successor have been elected or appointed: Katherine Goodrich

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 26,837,786WITHHELD: 728,533

Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Katherine Goodrich, M.D., MHS”): 26,837,786 for, 728,533 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,995,537 outstanding shares: 64% for, 2% withheld (66% of the company cast a for/withheld vote).

The 70 asset managers below cast 100% of the shares they voted on this item FOR (8,940,581 for, 0 against).

FOR 99.3%

FOR: 8,940,581 (99.3%)ABSTAIN: 58,501 (0.7%)

Largest asset managers voting on “To elect Class II directors, to serve until the 2028 annual meeting of stockholders or until their respective ” at Tarsus Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Vote
Vanguard	2,158,961	For
BlackRock	675,182	For
Lord Abbett	669,030	For
Fidelity	569,050	For
Invesco	560,136	For
Prudential/PGIM	542,762	For
Waddell & Reed	499,148	For
Artisan	421,491	For
T. Rowe Price	328,140	For
Charles Schwab	292,606	For
TIAA	269,344	For
Equitable	165,410	For
DRIEHAUS MUTUAL FUNDS	161,415	For
Delaware/Macquarie	150,000	For
Legg Mason	134,900	For
MoA Funds Corp	127,541	For
Allspring	124,103	For
First Trust	107,792	For
Ivy Variable Insurance Portfolios	86,002	For
Russell Investments	73,659	For
Baird	71,895	For
Securian Funds Trust	67,303	For
QUANTITATIVE MASTER SERIES LLC	63,024	For
SEI	52,645	For
Federated Hermes	51,104	For

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

5. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 34,718,262AGAINST: 125,755

Tarsus Pharmaceuticals, Inc.’s own tally for this item (“Proposal 4: Ratification of Ernst & Young LLP as our independent registered public accounting firm Our stockholders approved the ratification of the appointment of Ernst & Young LLP as our independent registered public a”): 34,718,262 for, 125,755 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 41,995,537 outstanding shares: 83% for, 0.3% against (83% of the company cast a for/against vote).

The 70 asset managers below cast 100% of the shares they voted on this item FOR (8,998,322 for, 0 against).

FOR 99.9%

FOR: 8,998,322 (100.0%)ABSTAIN: 760 (0.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at Tarsus Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Vote
Vanguard	2,158,961	For
BlackRock	675,182	For
Lord Abbett	669,030	For
Fidelity	569,050	For
Invesco	560,136	For
Prudential/PGIM	542,762	For
Waddell & Reed	499,148	For
Artisan	421,491	For
T. Rowe Price	328,140	For
Charles Schwab	292,606	For
TIAA	269,344	For
Equitable	165,410	For
DRIEHAUS MUTUAL FUNDS	161,415	For
Delaware/Macquarie	150,000	For
Legg Mason	134,900	For
MoA Funds Corp	127,541	For
Allspring	124,103	For
First Trust	107,792	For
Ivy Variable Insurance Portfolios	86,002	For
Russell Investments	73,659	For
Baird	71,895	For
Securian Funds Trust	67,303	For
QUANTITATIVE MASTER SERIES LLC	63,024	For
SEI	52,645	For
Federated Hermes	51,104	For

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

99.9% fund support · no official result

FOR 99.9%

The 4 asset managers below cast 99.9% of the shares they voted on this item FOR (559,856 for, 451 against).

FOR: 559,856 (99.9%)AGAINST: 451 (0.1%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Tarsus Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
ADAGE CAPITAL PARTNERS GP, L.L.C.	520,000	0	For
ESSEX INVESTMENT MANAGEMENT CO LLC	22,987	0	For
JPMorgan	16,869	0	For
Desjardins Global Asset Management Inc.	0	451	Against

Largest Tarsus Pharmaceuticals, Inc. shareholders voting in 2024-2025

Ranked by the number of Tarsus Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 41,995,537 shares outstanding at the time of that meeting.

Top Tarsus Pharmaceuticals, Inc. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	RTW INVESTMENTS, LP	7.64%
2	Vanguard	5.36%
3	Paradigm Biocapital Advisors LP	4.89%
4	BlackRock	4.10%
5	Frazier Life Sciences Management, L.P.	3.33%
6	JENNISON ASSOCIATES LLC	3.02%
7	Invesco	2.76%
8	LORD, ABBETT & CO. LLC	2.38%
9	Artisan	2.32%
10	MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	2.08%

Reported Tarsus Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Tarsus Pharmaceuticals, Inc. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Deep Track Capital, LP	8.57%	13G
RTW Investments, LP	8.15%	13G
BlackRock	7.51%	13F
Paradigm BioCapital Advisors LP	5.81%	DEF14A
JANUS HENDERSON GROUP PLC	5.34%	13G
Vanguard Group	5.30%	13F
Tang Capital Partners, LP	5.25%	DEF14A
Bobak Azamian	4.98%	DEF14A
Morgan Stanley	4.79%	13F
Cowen Financial Products LLC	4.55%	13G

Percentages above are of 41,995,537 shares outstanding, as reported by Tarsus Pharmaceuticals, Inc. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Tarsus Pharmaceuticals, Inc.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Tarsus Pharmaceuticals, Inc.'s shareholder meeting held 2025-06-12, in the 2024-2025 proxy season, 216 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,452 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Tarsus Pharmaceuticals, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To hold an advisory vote to approve, on a non-binding basis, the frequency with which future… — the reporting funds cast — of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Tarsus Pharmaceuticals, Inc. proxy season coverage: 2024-2025 (this page) · 2025-2026.